Ftse Mib
33.324,07
-1,37%
DAX
19.746,37
-1,27%
S&P 500
5.867,08
-0,09%
NASDAQ
19.372,77
-0,10%
Bitcoin
95.069,44
-2,45%
Pepperstone
Advertisement
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Palisade Bio Inc (PALI) Palisade Bio Inc (PALI) Notizie

PALI

Palisade Bio (PALI)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:PALI
DataOraFonteTitoloSimboloCompagnia
17/12/202423:30Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:PALIPalisade Bio Inc
17/12/202414:30GlobeNewswire Inc.Palisade Bio Appoints Brian Feagan, MD, FRCPC, to its Clinical Advisory BoardNASDAQ:PALIPalisade Bio Inc
17/12/202406:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:PALIPalisade Bio Inc
16/12/202422:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PALIPalisade Bio Inc
13/12/202422:05GlobeNewswire Inc.Palisade Bio Announces Closing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq RulesNASDAQ:PALIPalisade Bio Inc
13/12/202416:31Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:PALIPalisade Bio Inc
13/12/202415:57Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:PALIPalisade Bio Inc
12/12/202418:05GlobeNewswire Inc.Palisade Bio Announces Pricing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq RulesNASDAQ:PALIPalisade Bio Inc
09/12/202423:30Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:PALIPalisade Bio Inc
03/12/202414:15GlobeNewswire Inc.Palisade Bio Announces Preliminary Data from Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis Appears to be Safe and Well Tolerated in Treated SubjectsNASDAQ:PALIPalisade Bio Inc
22/11/202423:10Edgar (US Regulatory)Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectusesNASDAQ:PALIPalisade Bio Inc
22/11/202422:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PALIPalisade Bio Inc
21/11/202414:15GlobeNewswire Inc.Palisade Bio to Present Preclinical Results for PALI-2108 Demonstrating Engagement of Key Fibrotic Pathways of Crohn's Disease and Ulcerative Colitis (UC)NASDAQ:PALIPalisade Bio Inc
14/11/202421:35Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:PALIPalisade Bio Inc
14/11/202415:00GlobeNewswire Inc.Palisade Bio CMO Mitch Jones, MD, PhD, to Present at 8th Annual Antifibrotic Drug Development (AFDD) SummitNASDAQ:PALIPalisade Bio Inc
12/11/202414:45GlobeNewswire Inc.Palisade Bio Reports Third Quarter 2024 Financial Results and Outlines Key Accomplishments and Next Steps to Advance Lead Program PALI-2108NASDAQ:PALIPalisade Bio Inc
07/11/202414:30GlobeNewswire Inc.Palisade Bio Announces First Subject Dosed in Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis (UC)NASDAQ:PALIPalisade Bio Inc
31/10/202413:30GlobeNewswire Inc.Palisade Bio Announces Positive Data from Two Ex Vivo Translational Studies of PALI-2108 for the Treatment of Ulcerative ColitisNASDAQ:PALIPalisade Bio Inc
30/10/202411:05Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:PALIPalisade Bio Inc
15/10/202414:00GlobeNewswire Inc.Palisade Bio Announces Abstract Accepted for Presentation at the American College of Gastroenterology’s (ACG) 2024 Annual Scientific MeetingNASDAQ:PALIPalisade Bio Inc
10/10/202414:30GlobeNewswire Inc.Palisade Bio Cleared by Health Canada to Commence Phase 1 Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis (UC)NASDAQ:PALIPalisade Bio Inc
08/10/202414:00GlobeNewswire Inc.Palisade Bio to Participate in the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLCNASDAQ:PALIPalisade Bio Inc
25/09/202414:00GlobeNewswire Inc.Palisade Bio Provides Update on Progress Toward Launch of Phase 1 Human Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative ColitisNASDAQ:PALIPalisade Bio Inc
16/09/202414:00GlobeNewswire Inc.Palisade Bio Launches New Corporate Branding and Reiterates Commitment to Advancing Next-Generation Precision TherapiesNASDAQ:PALIPalisade Bio Inc
05/09/202414:00GlobeNewswire Inc.Palisade Bio Reports Data Demonstrating PDE4B Expression in Patient Cohorts Could be Utilized as a Potential Marker for Patient StratificationNASDAQ:PALIPalisade Bio Inc
19/08/202414:00GlobeNewswire Inc.Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:PALIPalisade Bio Inc
13/08/202414:05GlobeNewswire Inc.Palisade Bio Reports Second Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:PALIPalisade Bio Inc
12/08/202422:11Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PALIPalisade Bio Inc
08/08/202414:00GlobeNewswire Inc.Palisade Bio Selects Dose for Upcoming Phase 1 Clinical Study of PALI-2108 for Ulcerative ColitisNASDAQ:PALIPalisade Bio Inc
31/07/202415:15GlobeNewswire Inc.Palisade Bio Participates in Virtual Investor “What this Means” SegmentNASDAQ:PALIPalisade Bio Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:PALI

La tua Cronologia

BIT
ISP
Intesa Sanpaolo
BIT
UCG
Unicredit
BIT
SPM
Saipem
BIT
STLAM
Stellantis NV
BIT
ENI
Eni
BIT
ENEL
Enel
BIT
TIT
Telecom Italia
BIT
BPE
Bper Banca
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
BAMI
Banco BPM
BIT
STMMI
ST Microelectronics
BIT
RACE
Ferrari NV
BIT
IVG
Iveco Group NV
BIT
FBK
Finecobank
BIT
MONC
Moncler
BIT
PRY
Prysmian
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network